虫衍生分子改善了5甲治疗对实验性结肠瘤发生的改善
Mónica G Mendoza-Rodríguez1, Daniela Medina-Reyes1, Cuauhtémoc A Sánchez-Barrera1
1Unidad de Biomedicina, Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México, Avenida de los Barrios 1, Los Reyes Iztacala, Tlalnepantla 54090, Mexico.
概括
这项研究表明,虫分子可以提高5-甲 (5FU) 化疗对结肠癌的有效性. 这种组合疗法减少了瘤的生长,并增强了抗癌免疫反应.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 寄生虫学的寄生虫学
背景情况:
- 结肠直肠癌 (CRC) 仍然是全球癌症死亡的主要原因.
- 目前用于CRC的5-甲 (5FU) 化疗疗效果有限,并且经常遇到药物耐药性.
- 需要辅助疗法来改善CRC治疗结果.
研究的目的:
- 研究虫衍生的Taenia crassiceps (TcES) 分子作为5FU的辅助剂,用于治疗晚期结肠炎相关的结肠癌的潜力.
- 评估TcES+5FU治疗对瘤标记物,免疫细胞活性和信号通路 in vivo 和 in vitro 的影响.
主要方法:
- 在体内研究使用与结肠炎相关的结肠癌模型,用TcES+5FU治疗.
- 分析细胞因子表达 (Il-10,Tgf-β,Tnf-α,Il-17a),瘤标记物 (cyclin D1,Ki67) 和NK细胞活性 (Granzyme B1).
- 在体外对人类结肠癌细胞系进行测试,以评估扩散和迁移,重点关注P53和P21通路.
主要成果:
- TcES+5FU降低了免疫抑制性细胞因子 (Il-10,Tgf-β) 和促炎性细胞因子 (Tnf-α,Il-17a) 的下调.
- 治疗降低了恶性瘤标记物 (cyclin D1,Ki67),抑制了β-catenin通路,并通过降低Mdm2.2恢复了P53活性.
- 增强的NK细胞招募和Granzyme B1释放导致瘤细胞死亡;在体外,TcES+5FU通过P53/P21调制减少了增殖和迁移.
结论:
- 虫衍生TcES分子可以在已建立的结肠瘤中增强5FU的抗癌作用.
- TcES+5FU疗法通过调节瘤微环境和增强抗瘤免疫力来改善CRC治疗的有希望的策略.
- 这项研究突出了寄生虫产品作为瘤学新型治疗剂的潜力.
相关概念视频
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:15Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...